Literature DB >> 27599390

A novel cytokine profile associated with cancer metastasis to mediastinal and hilar lymph nodes identified using fine needle aspiration biopsy - A pilot study.

Ali I Saeed1, Fares Qeadan2, Akshay Sood3, Dorothy J VanderJagt4, Shiraz I Mishra5, Deirdre A Hill6, Tobias Peikert7, Mohan L Sopori8.   

Abstract

Cancer metastasis to the lymph nodes is indicative of a poor prognosis. An endobronchial ultrasound-guided fine needle aspiration (EBUS-FNA) biopsy is increasingly being used to sample paratracheal lymph nodes for simultaneous cancer diagnosis and staging. In this prospective, single-center study, we collected dedicated EBUS-FNA biopsies from 27 patients with enlarged paratracheal and hilar lymph nodes. Cytokines were assayed using Bio-Plex Pro human cancer biomarker panels (34 cytokines), in a Bio-Rad 200 suspension array system. A mean cytokine value was taken from each subject with more than 1 lymph node station EBUS-FNA biopsies. Malignant and benign histologic diagnoses were established in 16 and 12 patients, respectively. An initial analysis using the Kruskal-Wallis test with Sidak correction for multiple comparisons, showed significant elevation of sVEGFR-1, IL-6, VEGF-A, Angiopoeintin-2, uPA, sHER-2/neu and PLGF in malignant lymph node samples compared to benign samples. The univariate logistic regression analyses revealed that 6 cytokines were significant predictors and 1 cytokine (PLGF) was marginally significant for discrimination between benign and malignant samples. The prediction power of these cytokines as biomarkers were very high according to the area under the ROC curve. Multiple logistic regression for subsets of the seven cytokine combined; provided an almost complete discrimination between benign and malignant samples (AUC=0.989). For screening and diagnostic purposes, we presented the optimal discrimination cut-off for each cytokine: sVEGFR-1 (2124.5pg/mL), IL-6 (40.2pg/mL), VEGF-A (1060.1pg/mL), Angiopoeintin-2 (913.7pg/mL), uPA (248.1pg/mL), sHER-2/neu (5010pg/mL) and PLGF (93.4pg/mL). For the very first time, a novel cytokine profile associated with cancer metastasis to the paratracheal lymph nodes were reported.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarker profile; Endobronchial ultrasound; Fine needle aspiration biopsy; Lymphatic metastasis

Mesh:

Substances:

Year:  2016        PMID: 27599390     DOI: 10.1016/j.cyto.2016.08.011

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  5 in total

1.  Oral sampling methods are associated with differences in immune marker concentrations.

Authors:  Carole Fakhry; Fares Qeadan; Robert H Gilman; Pablo Yori; Margaret Kosek; Nicole Patterson; David W Eisele; Christine G Gourin; Chandala Chitguppi; Morgan Marks; Patti Gravitt
Journal:  Laryngoscope       Date:  2017-11-24       Impact factor: 3.325

2.  Middle Cerebral Artery Aneurysm "Neck Overhang": Decreased Postclipping Residual Using the Intersecting Clipping Technique.

Authors:  Stavros Dimitriadis; Fares Qeadan; Christopher L Taylor; Howard Yonas; Andrew P Carlson
Journal:  Oper Neurosurg (Hagerstown)       Date:  2018-10-01       Impact factor: 2.703

3.  Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex.

Authors:  Aaron C Petrey; Fares Qeadan; Elizabeth A Middleton; Irina V Pinchuk; Robert A Campbell; Ellen J Beswick
Journal:  J Leukoc Biol       Date:  2020-09-15       Impact factor: 4.962

4.  High-Risk Features of Delayed Clinical Progression in Cerebral Venous Thrombosis: A Proposed Prediction Score for Early Intervention.

Authors:  Saif A Bushnaq; Fares Qeadan; Tapan Thacker; Mohammad Abbas; Andrew P Carlson
Journal:  Interv Neurol       Date:  2018-04-20

5.  The MK2 pathway is linked to G-CSF, cytokine production and metastasis in gastric cancer: a novel intercorrelation analysis approach.

Authors:  Fares Qeadan; Pranshu Bansal; Joshua A Hanson; Ellen J Beswick
Journal:  J Transl Med       Date:  2020-03-26       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.